Michael J. Morris, MD | Authors

July 03, 2020

Results of phase 3 CONDOR study could have a far-reaching impact on patients with prostate cancer.

June 04, 2020

An analysis of the secondary endpoint of the phase III CONDOR study showed PSMA scans had a profound impact on patient care.

June 30, 2014

Dr. Morris discusses results and implications of the CHAARTED trial, which studied the survival impact of androgen deprivation therapy (ADT) plus docetaxel vs ADT alone for hormone-sensitive newly metastatic prostate cancer.